Latest MPM ONCOLOGY IMPACT MANAGEMENT LP Stock Portfolio
MPM ONCOLOGY IMPACT MANAGEMENT LP Performance:
2024 Q3: 3.29%YTD: 13.23%2023: -9.45%
Performance for 2024 Q3 is 3.29%, and YTD is 13.23%, and 2023 is -9.45%.
About MPM ONCOLOGY IMPACT MANAGEMENT LP and 13F Hedge Fund Stock Holdings
MPM BIOIMPACT LLC is a hedge fund based in CHESTNUT HILL, MA. On 29-Mar-2021, the fund reported that it had an AUM (Regulated Assets under Management) of $1.2 Billions. In it's latest 13F Holdings report, MPM BIOIMPACT LLC reported an equity portfolio of $666.6 Millions as of 30 Sep, 2024.
The top stock holdings of MPM BIOIMPACT LLC are CGEM, INSM, OLMA. The fund has invested 19.2% of it's portfolio in CULLINAN THERAPEUTICS, INC. and 6.7% of portfolio in INSMED INCORPORATED.
The fund managers got completely rid off ALKERMES PLC (ALKS), MORPHIC HOLDING INC (MORF) and AVADEL PHARMACEUTICALS PLC (AVDL) stocks. They significantly reduced their stock positions in REGENXBIO INC. (RGNX), 89BIO INC (ETNB) and INTELLIA THERAPEUTICS, INC. (NTLA). MPM BIOIMPACT LLC opened new stock positions in ROCKET PHARMACEUTICALS, INC. (RCKT), TWIST BIOSCIENCE CORP (TWST) and AQUESTIVE THERAPEUTICS INC (AQST). The fund showed a lot of confidence in some stocks as they added substantially to AVIDITY BIOSCIENCES INC (RNA), CARTESIAN THERAPEUTICS INC (SELB) and RELAY THERAPEUTICS INC. (RLAY).
The top stock holdings of MPM BIOIMPACT LLC are CGEM, INSM, OLMA. The fund has invested 19.2% of it's portfolio in CULLINAN THERAPEUTICS, INC. and 6.7% of portfolio in INSMED INCORPORATED.
The fund managers got completely rid off ALKERMES PLC (ALKS), MORPHIC HOLDING INC (MORF) and AVADEL PHARMACEUTICALS PLC (AVDL) stocks. They significantly reduced their stock positions in REGENXBIO INC. (RGNX), 89BIO INC (ETNB) and INTELLIA THERAPEUTICS, INC. (NTLA). MPM BIOIMPACT LLC opened new stock positions in ROCKET PHARMACEUTICALS, INC. (RCKT), TWIST BIOSCIENCE CORP (TWST) and AQUESTIVE THERAPEUTICS INC (AQST). The fund showed a lot of confidence in some stocks as they added substantially to AVIDITY BIOSCIENCES INC (RNA), CARTESIAN THERAPEUTICS INC (SELB) and RELAY THERAPEUTICS INC. (RLAY).
MPM ONCOLOGY IMPACT MANAGEMENT LP Annual Return Estimates Vs S&P 500
Our best estimate is that MPM BIOIMPACT LLC made a return of 3.29% in the last quarter. In trailing 12 months, it's portfolio return was 28.65%.
New Buys
| Ticker | $ Bought |
|---|---|
| rocket pharmaceuticals, inc. | 19,695,900 |
| twist bioscience corp | 13,324,900 |
| aquestive therapeutics inc | 8,947,820 |
| janux therapeutics inc | 7,773,300 |
| xenon pharmaceuticals inc | 6,527,550 |
| stoke therapeutics inc | 5,892,460 |
| wave life sciences pte ltd | 5,120,660 |
| arcturus therapeutics holdings | 5,094,780 |
New stocks bought by MPM ONCOLOGY IMPACT MANAGEMENT LP
Additions
| Ticker | % Inc. |
|---|---|
| avidity biosciences inc | 451 |
| cartesian therapeutics inc | 142 |
| relay therapeutics inc. | 59.52 |
| edgewise therapeutics inc | 23.83 |
| compass therapeutics, inc. | 12.72 |
| alx oncology holdings inc. | 10.5 |
| disc medicine inc | 2.00 |
| trevi therapeutics inc | 1.88 |
Additions to existing portfolio by MPM ONCOLOGY IMPACT MANAGEMENT LP
Reductions
| Ticker | % Reduced |
|---|---|
| regenxbio inc. | -91.02 |
| 89bio inc | -70.58 |
| intellia therapeutics, inc. | -39.67 |
| ultragenyx pharmaceutical inc | -13.35 |
| sutro biopharma, inc. | -6.94 |
| crinetics pharmaceuticals inc. | -5.62 |
| guardant health inc | -0.17 |
MPM ONCOLOGY IMPACT MANAGEMENT LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| xeris biopharma holdings inc | -10,868,700 |
| fulcrum therapeutics inc | -8,958,080 |
| scholar rock holding corp | -8,565,990 |
| avadel pharmaceuticals plc | -11,012,400 |
| hillevax inc | -9,327,930 |
| verve therapeutics, inc | -3,114,240 |
| alkermes plc | -13,437,100 |
| immatics nv | -4,854,950 |
MPM ONCOLOGY IMPACT MANAGEMENT LP got rid off the above stocks
Sector Distribution
MPM BIOIMPACT LLC has about 97.7% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 97.7 |
| Others | 2.3 |
Market Cap. Distribution
MPM BIOIMPACT LLC has about 10.1% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 46.5 |
| MID-CAP | 32.7 |
| LARGE-CAP | 10.1 |
| MICRO-CAP | 6.9 |
| UNALLOCATED | 2.3 |
| NANO-CAP | 1.5 |
Stocks belong to which Index?
About 82.8% of the stocks held by MPM BIOIMPACT LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 82.8 |
| Others | 17.2 |
MPM ONCOLOGY IMPACT MANAGEMENT LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of MPM ONCOLOGY IMPACT MANAGEMENT LP
MPM BIOIMPACT LLC has 43 stocks in it's portfolio. About 55.8% of the portfolio is in top 10 stocks. ALXO proved to be the most loss making stock for the portfolio. EWTX was the most profitable stock for MPM BIOIMPACT LLC last quarter.
Last Reported on: 13 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ADAP | adaptimmune therapeutics plc | 0.73 | 5,095,910 | 4,841,120 | unchanged | 0.00 | ||
| AKRO | akero therapeutics inc | 1.69 | 392,544 | 11,262,100 | added | 1.7 | ||
| ALKS | alkermes plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALLK | allakos | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALXO | alx oncology holdings inc. | 0.66 | 2,409,860 | 4,385,950 | added | 10.5 | ||
| AQST | aquestive therapeutics inc | 1.34 | 1,796,750 | 8,947,820 | new | |||
| ARCT | arcturus therapeutics holdings | 0.76 | 219,508 | 5,094,780 | new | |||
| AVDL | avadel pharmaceuticals plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AXSM | axsome therapeutics, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CGEM | cullinan therapeutics, inc. | 19.21 | 7,648,270 | 128,032,000 | unchanged | 0.00 | ||
| CMPX | compass therapeutics, inc. | 1.56 | 5,641,890 | 10,381,100 | added | 12.72 | ||
| CRNX | crinetics pharmaceuticals inc. | 4.03 | 525,845 | 26,870,700 | reduced | -5.62 | ||
| ETNB | 89bio inc | 0.37 | 330,000 | 2,442,000 | reduced | -70.58 | ||
| EWTX | edgewise therapeutics inc | 3.67 | 917,166 | 24,479,200 | added | 23.83 | ||
| FULC | fulcrum therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| GH | guardant health inc | 1.72 | 499,170 | 11,451,000 | reduced | -0.17 | ||
| HLVX | hillevax inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| HOWL | werewolf therapeutics, inc. | 0.76 | 2,388,010 | 5,062,580 | unchanged | 0.00 | ||
| INSM | insmed incorporated | 6.74 | 615,391 | 44,923,500 | unchanged | 0.00 | ||
| IOVA | iovance biotherapeutics inc | 3.39 | 2,406,710 | 22,599,000 | added | 1.69 | ||